Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Authors

Showing 4 results for author "Kumar Anmol".

Back to authors

Thumbnail for Clinical Outcomes Following Ibrutinib Withdrawal in Mantle Cell Lymphoma: A TriNetX Analysis

MCL - 1233

Clinical Outcomes Following Ibrutinib Withdrawal in Mantle Cell Lymphoma: A TriNetX Analysis

Kumar Anmol

Poster Presenter: Kumar Anmol

Thumbnail for Pirtobrutinib-First vs Brexucabtagene Autoleucel-First Sequencing Post Covalent BTK Inhibitor Failure in Mantle Cell Lymphoma: A Propensity-Matched Real-World Analysis

MCL - 1257

Pirtobrutinib-First vs Brexucabtagene Autoleucel-First Sequencing Post Covalent BTK Inhibitor Failure in Mantle Cell Lymphoma: A Propensity-Matched Real-World Analysis

Kumar Anmol

Poster Presenter: Kumar Anmol

Thumbnail for Comparative Outcomes With Luspatercept Versus Erythropoiesis-Stimulating Agents in Lower-Risk Myelodysplastic Syndromes: A Propensity Score-Matched Retrospective Cohort Study

MDS - 1271

Comparative Outcomes With Luspatercept Versus Erythropoiesis-Stimulating Agents in Lower-Risk Myelodysplastic Syndromes: A Propensity Score-Matched Retrospective Cohort Study

Kumar Anmol

Poster Presenter: Kumar Anmol

Thumbnail for Survival and Toxicity Outcomes With Hypomethylating Agent Plus Venetoclax vs Hypomethylating Agent Alone in Higher-Risk Myelodysplastic Syndrome: A Propensity-Matched Retrospective Cohort Study

MDS - 1311

Survival and Toxicity Outcomes With Hypomethylating Agent Plus Venetoclax vs Hypomethylating Agent Alone in Higher-Risk Myelodysplastic Syndrome: A Propensity-Matched Retrospective Cohort Study

Kumar Anmol

Poster Presenter: Kumar Anmol

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.